×
HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
https://ascopost.com/news/may-2020/hif2a-inhibitor-for-von-hippel-lindau-disease-associated-renal-cell-carcinoma/

May 29th, 2020 - In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC).

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair
https://ascopost.com/videos/asco20-virtual-scientific-program/merry-jennifer-markham-perspectives-on-three-abstracts/

May 29th, 2020 - Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.

Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy
https://ascopost.com/videos/asco20-virtual-scientific-program/fatima-cardoso-on-mammaprint-as-guidance-for-adjuvant-chemotherapy/

May 29th, 2020 - Fatima Cardoso, MD, of Lisbon’s Champalimaud Cancer Center, discusses the long-term results of MINDACT, a large prospective trial showing the clinical utility of the 70-gene signature MammaPrint for adjuvant chemotherapy decision-making. The primary distant metastasis–free survival endpoint at 5 years continued to be met in chemotherapy-untreated women with clinical-high/genomic-low risk diseas...

Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers
https://ascopost.com/news/may-2020/data-from-tapur-study-cohorts-on-olaparib-for-brca-mutated-advanced-prostate-and-pancreatic-cancers/

May 29th, 2020 - Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) study provide real-world evidence to support recent clinical trial data that demonstrate a role for olaparib in the treatment of advanced prostate and pancreatic cancers with BRCA1/2-inactivating mutations. The findings were presented during the ASCO20 Virtual Scientific Program (Abstract 5567, Ab...

Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
https://ascopost.com/news/may-2020/tepotinib-shows-activity-in-patients-with-nsclc-and-met-exon-14-skipping-mutation/

May 28th, 2020 - Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program (Abstract 9556) and published simultaneously by Paik et al in The New England Journal of Medicine.

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/jeffrey-meyerhardt-on-celecoxib-and-folfox-for-stage-iii-colon-cancer/

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard chemotherapy did not significantly improve disease-free or overall survival (Abstract 4003).

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone
https://ascopost.com/videos/asco20-virtual-scientific-program/shaji-kumar-on-carfilzomib-lenalidomide-bortezomib-and-dexamethasone-in-multiple-myeloma/

May 29th, 2020 - Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine
https://ascopost.com/videos/asco20-virtual-scientific-program/nancy-lin-on-tucatinib-trastuzumab-and-capecitabine-for-metastatic-breast-cancer/

May 29th, 2020 - Nancy U. Lin, MD, of Dana-Farber Cancer Institute, discusses the HER2CLIMB study of patients with previously treated HER2-positive metastatic breast cancer that had metastasized to the brain. Adding tucatinib to trastuzumab and capecitabine doubled the intracranial response rate and reduced the risk of death by nearly half, compared with trastuzumab plus capecitabine (Abstract 1005).

Intensive Remote Monitoring of High-Risk Patients Initiating Antineoplastic Treatment
https://ascopost.com/news/may-2020/intensive-remote-monitoring-of-high-risk-patients-initiating-antineoplastic-treatment/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Robert Michael Daly, MD, MBA, and colleagues (Abstract 2027), use of a pilot program of intensive remote monitoring of high-risk outpatients receiving antineoplastic treatment has shown considerable promise in the ability to improve patient care and decrease use of hospital resources by promptly alerting practitioners to symptoms that requ...

Precision Medicine on a Large Scale for Pediatric Patients With Cancer
https://ascopost.com/news/may-2020/precision-medicine-on-a-large-scale-for-pediatric-patients-with-cancer/

May 28th, 2020 - Although 84% of children with cancer survive 5 years or more, children with refractory, relapsed, and progressive high-risk malignancies have a poor median survival of 9.5 months. The German INFORM registry is a large prospective, noninterventional, multicenter study collecting clinical and molecular data on pediatric patients with refractory, relapsed, and progressive malignant cancers. The st...

Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
https://ascopost.com/news/may-2020/patients-with-cancer-especially-progressive-disease-infected-with-covid-19-may-have-an-increased-risk-of-death/

May 28th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 28th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage Ib–IIIa EGFR Mutation–Positive Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/roy-herbst-on-osimertinib-in-stage-ib-iiia-egfr-mutation-positive-nsclc/

May 29th, 2020 - Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care
https://ascopost.com/videos/asco20-virtual-scientific-program/christopher-sweeney-and-thomas-powles-on-avelumab-vs-best-supportive-care-in-urothelial-cancer/

May 29th, 2020 - Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared with 14.3 months with best supportive care (Abstract LBA1).

New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200180/full/

May 28th, 2020 - DESKTOP III became the first phase III, prospective, randomized trial to show an association between improved overall survival (OS) and secondary cytoreductive surgery in women with platinum-sensitive recurrent ovarian cancer (PSROC), offering hope for people with a condition that results in nearly 14,000 deaths annually. Data were presented during the ASCO20 Virtual Scientific Program (Abstrac...

Palliative Care Improves Well-Being and QoL in Phase I Cancer Trial Participants
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200184/full/

May 28th, 2020 - Participants in phase I oncology trials represent a patient population new to palliative care. These patients typically have remarkable symptoms, with a symptom burden comparable to other patients with cancer.1 Thomas J. Smith, MD, FASCO, of Johns Hopkins University, presented the results of a randomized trial evaluating a palliative care intervention (PCI) compared with usual care (UC) for pat...

Effect of Veliparib With or Without Cisplatin in Breast Cancer: Results of SWOG S1416
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200176/full/

May 28th, 2020 - The Southwest Oncology Group (SWOG) 1416 phase II trial was designed to compare the efficacy of the PARP inhibitor veliparib plus cisplatin versus cisplatin alone in patients with metastatic and/or locally recurrent triple-negative breast cancer (TNBC) or BRCA1 or BRCA2 germline mutation–associated HER2-negative metastatic breast cancer. Priyanka Sharma, MD, of the University of Kansas Medical ...

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200193/full/

May 28th, 2020 - Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005). Clinically meaningful improvement in PFS was observed in all subgroups tested, including patients who did not receive a...